Carbimazole 10mg tablets
Requires a prescription from a doctor or prescriber
An imidazole antithyroid agent.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Carbimazole
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Carbimazole
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
9 branded products available
MHRA licensed products
View all licensed products for Carbimazole on the MHRA register
Carbimazole 10mg tablets
Carbimazole 10mg tablets
Carbimazole 10mg tablets
Carbimazole 10mg tablets
Carbimazole 10mg tablets
Carbimazole 10mg tablets
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
15 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 8 · Randomised trials: 1 · 1977–2026
Showing the 50 most relevant studies, sorted by most relevant.
Alan M. McGregor, Meryl M. Petersen, Sandra M. McLachlan, et al.
New England Journal of Medicine, 1980
- Antibody Formation
- Autoantibodies
- Carbimazole
Nicola Foulds, Ian Walpole, Frances Elmslie, et al.
American Journal of Medical Genetics Part A, 2004
- Abnormalities, Drug-Induced
- Carbimazole
- Ear
B. Marchant, B. E. W. Brownlie, D. M. Hart, et al.
The Journal of Clinical Endocrinology & Metabolism, 1977
- Maternal-Fetal Exchange
- Abortion, Induced
- Carbimazole
Stefan K. Grebe, Colin M. Feek, Henry C. Ford, et al.
Clinical Endocrinology, 1998
- Carbimazole
- Graves Disease
- Recurrence
Arie Berghout, Wilmar M. Wiersinga, J. L. Touber, et al.
The Lancet, 1990
- Carbimazole
- Goiter
- Placebos
Bassem Al Hariri, M. Elhassan, Hadil Altaj Altrify Alsidig, et al.
Clinical Case Reports, 2025
Carbimazole, a thionamide derivative, is widely used for hyperthyroidism but carries a rare risk of hepatotoxicity, including cholestatic injury. A 42‐year‐old man developed severe cholestatic jaundice 4 weeks after carbimazole initiation. Laboratory findings showed marked hyperbilirubinemia (peak: 650 μmol/L) with elevated ALP (366 U/L). Viral, autoimmune, and biliary causes were excluded. Liver biopsy confirmed cholestasis. Carbimazole was discontinued, corticosteroids initiated, and radioiodine therapy planned. Bilirubin levels gradually improved over 8 weeks. Carbimazole‐induced cholestasis, though rare, necessitates prompt recognition and alternative hyperthyroidism management. Routine liver monitoring is crucial.
Abstract licence: CC BY
Mittal L, Jasuja S
2025
- Hyperthyroidism
- Carbimazole
- Antithyroid Agents
A. Akmal, J. Kung
Expert Opinion on Drug Safety, 2014
- Carbimazole
- Drug Labeling
- Hyperthyroidism
C P van Dijke, ROB J. HEYDENDAEL, MARTIN J. DE KLEINE
Annals of Internal Medicine, 1987
- Carbimazole
- Hyperthyroidism
- Maternal-Fetal Exchange
Simon H. S. Pearce
Clinical Endocrinology, 2004
- Agranulocytosis
- Carbimazole
- United Kingdom
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
95 found
Half-life
Not available
Mechanism
Carbimazole is an aitithyroid agent that decreases the uptake and concentration…
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Protein binding
85%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 447 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC H03BB01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Carbimazole
Additional database identifiers
ChemSpider
28829
BindingDB
50275889
ZINC
ZINC000000001091
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12015
GenAtlas
TPO
GeneCards
TPO
GenBank Gene Database
J02969
GenBank Protein Database
339867
Guide to Pharmacology
2526
UniProt Accession
PERT_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2594
GenAtlas
CYP19A1
GeneCards
CYP19A1
GenBank Gene Database
M22246
GenBank Protein Database
179002
Guide to Pharmacology
1362
UniProt Accession
CP19A_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q414013), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.